RS52192B - The use of IL-18BP isoforms for the therapy and / or prevention of neurologic inflammatory diseases - Google Patents

The use of IL-18BP isoforms for the therapy and / or prevention of neurologic inflammatory diseases

Info

Publication number
RS52192B
RS52192B RS20120014A RSP20120014A RS52192B RS 52192 B RS52192 B RS 52192B RS 20120014 A RS20120014 A RS 20120014A RS P20120014 A RSP20120014 A RS P20120014A RS 52192 B RS52192 B RS 52192B
Authority
RS
Serbia
Prior art keywords
seq
polypeptide
amino acids
amino acid
mutein
Prior art date
Application number
RS20120014A
Other languages
English (en)
Serbian (sr)
Inventor
Yolande Chvatchko
Yves Sagot
Anne Corbaz
Original Assignee
Merck Serono Sa.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Serono Sa. filed Critical Merck Serono Sa.
Publication of RS52192B publication Critical patent/RS52192B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Cell Biology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RS20120014A 2005-06-03 2006-06-02 The use of IL-18BP isoforms for the therapy and / or prevention of neurologic inflammatory diseases RS52192B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05104863 2005-06-03
US68805705P 2005-06-07 2005-06-07
PCT/EP2006/062864 WO2006128911A2 (en) 2005-06-03 2006-06-02 Use of il-18bp isoforms for the treatment and/or prevention of neurological inflammatory diseases

Publications (1)

Publication Number Publication Date
RS52192B true RS52192B (en) 2012-10-31

Family

ID=35058651

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20120014A RS52192B (en) 2005-06-03 2006-06-02 The use of IL-18BP isoforms for the therapy and / or prevention of neurologic inflammatory diseases

Country Status (17)

Country Link
US (1) US8128920B2 (es)
EP (1) EP1888100B1 (es)
JP (1) JP5048658B2 (es)
AT (1) ATE530227T1 (es)
AU (1) AU2006254106B2 (es)
CA (1) CA2610691C (es)
CY (1) CY1112128T1 (es)
DK (1) DK1888100T3 (es)
ES (1) ES2376534T3 (es)
HR (1) HRP20110788T1 (es)
IL (1) IL187839A (es)
NO (1) NO339540B1 (es)
PL (1) PL1888100T3 (es)
PT (1) PT1888100E (es)
RS (1) RS52192B (es)
SI (1) SI1888100T1 (es)
WO (1) WO2006128911A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030105057A1 (en) * 1997-03-19 2003-06-05 Yale University Methods and compositions for stimulating apoptosis and cell death or for inhibiting cell growth and cell attachment
IL121860A0 (en) 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
JP4216950B2 (ja) * 1998-09-01 2009-01-28 株式会社林原生物化学研究所 インターロイキン−１８結合蛋白質
CA2340579A1 (en) 1998-09-01 2000-03-09 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin 18-binding protein
PE20011350A1 (es) * 2000-05-19 2002-01-15 Vertex Pharma PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
AU2002224417A1 (en) * 2000-10-18 2002-04-29 Immunex Corporation Methods for treating il-18 mediated disorders
KR20040030625A (ko) * 2001-05-25 2004-04-09 아레스 트레이딩 에스.에이. Ｃｎｓ 손상을 치료하거나 예방하기 위한 ｉｌ-18저해물질의 용도
JP5074030B2 (ja) 2003-05-13 2012-11-14 メルク セローノ ソシエテ アノニム Ｉｌ−１８結合タンパク質の活性変異体とその医学的応用

Also Published As

Publication number Publication date
CA2610691C (en) 2015-12-01
ES2376534T3 (es) 2012-03-14
HRP20110788T1 (hr) 2011-11-30
EP1888100B1 (en) 2011-10-26
NO339540B1 (no) 2016-12-27
CY1112128T1 (el) 2015-11-04
PL1888100T3 (pl) 2012-03-30
DK1888100T3 (da) 2012-01-23
US8128920B2 (en) 2012-03-06
IL187839A0 (en) 2008-03-20
JP5048658B2 (ja) 2012-10-17
US20080233085A1 (en) 2008-09-25
AU2006254106B2 (en) 2012-04-26
WO2006128911A2 (en) 2006-12-07
JP2008542340A (ja) 2008-11-27
WO2006128911A3 (en) 2007-03-29
SI1888100T1 (sl) 2012-01-31
AU2006254106A1 (en) 2006-12-07
CA2610691A1 (en) 2006-12-07
PT1888100E (pt) 2011-12-15
AU2006254106A8 (en) 2008-04-03
IL187839A (en) 2013-03-24
ATE530227T1 (de) 2011-11-15
EP1888100A2 (en) 2008-02-20
NO20076387L (no) 2008-02-29

Similar Documents

Publication Publication Date Title
Tan et al. Venom-gland transcriptome and venom proteome of the Malaysian king cobra (Ophiophagus hannah)
HRP20161807T1 (hr) Produljeni rekombinantni polipeptidi i sastavi koji ih sadrže
DE69717092T2 (de) Gebrauch einer pharmazeutischen Zusammensetzung, enthaltend ein appetitzügelndes Peptid
US20150111821A1 (en) Mutated fibroblast growth factor (fgf) 1 and methods of use
Rodrigues et al. Bactericidal and neurotoxic activities of two myotoxic phospholipases A2 from Bothrops neuwiedi pauloensis snake venom
DE69628576T2 (de) Procollagene
CN103415300A (zh) N-末端修饰的fgf21化合物
US20090305352A1 (en) Activated collagen scaffold materials and their special fused active restoration factors
AR071127A1 (es) Metodos de uso de un receptor acoplado a proteina g para identificar secretagogos del peptido yy(pyy) y compuestos utiles en el tratamiento de afecciones moduladas por pyy
WO2013006486A3 (en) Compositions, uses and methods for treatment of metabolic disorders and diseases
NZ596778A (en) Glucose-regulating polypeptides and methods of making and using same
AR040446A1 (es) Defensinas de plantas
DE112005000737T5 (de) Mit Heparansulfat-Zuckerketten modifizierte Heparin-bindende Proteine, Verfahren zur Erzeugung derselben und Arzneimittel, welche dieselben enthalten
HRP20100644T1 (hr) Cijepivo kombinacije peptida protiv alergije na macke
JPH08503198A (ja) Ｏｐ−３誘導形態形成
JP2005511614A (ja) 新規な上皮細胞増殖因子タンパク質及び遺伝子、及びその使用方法
WO2015061331A1 (en) Chimeric fibroblast growth factor (fgf) 2/fgf1 peptides and methods of use
JP5992529B2 (ja) ポリペプチド、足場組成物、軟骨組織修復用組成物、軟骨細胞培養用組成物及びグリコサミノグリカン産生促進用組成物
JP2010508845A (ja) ヘパリン結合配列に融合した増殖因子を使用して心臓修復を促進する方法
Miele et al. Expression of Bv8 in Pichia pastoris to identify structural features for receptor binding
RS52192B (en) The use of IL-18BP isoforms for the therapy and / or prevention of neurologic inflammatory diseases
AR087719A2 (es) Celula de planta transformada, cultivo de tejidos y planta transgenica
JPH0995454A (ja) 抗潰瘍組成物
Liu et al. The repairing effect of a recombinant human connective‐tissue growth factor in a burn‐wounded rhesus‐monkey (Macaca mulatta) model
ATE338770T1 (de) Mit bh4 fusionierte polypeptide